Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages

Completed · Phase 1

Conditions studied: Acute Mountain Sickness

In brief

This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California

Key facts

Study ID

NCT03424226

Run by

Stanford University

People needed

105

Starts

2018-08-04

Expected to finish

2018-09-30

Last updated by the study team

2018-11-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-75 healthy non-pregnant volunteer
• live at low elevation < 4000 ft
• Arrange your own transportation to WMRS (Bishop) by Friday evening of study weekend
• Available for full study duration (Friday PM-Sunday AM)

You may not qualify if…

• Age <18 or >75, Pregnant, Live at altitude >4000 ft Slept at altitude > 4000ft within 1 week of study Allergic to acetazolamide, sulfa drugs, Taking non-steroidal anti-inflammatory drugs, Acetazolamide, or Corticosteroids 1 week prior to study

Where it is running

• Stanford University — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.